Latest MS research news

Latest MS research news | 07 May 2014

Daclizumab high-yield process in relapsing-remitting multiple sclerosis

This study shows that the safety profile of daclizumab HYP is consistent with other studies of daclizumab with respect to reports of immune-mediated adverse events primarily involving the skin and hepatic systems.

From MSIF

Latest MS research news | 07 May 2014

Exploring brainstem function in multiple sclerosis

As demyelinating lesions can exist below the threshold for detection in clinical examination and conventional MRI, the data indicate that the paired use of the brainstem reflexes/evoked potential batteries could help in detection accuracy of brainstem dysfunction.

From MSIF

Latest MS research news | 07 May 2014

Diagnosis and classification of neuromyelitis optica

The review highlights the importance of a correct diagnosis of neuromyelitis optica. The diagnostic criteria of Wingerchuk include clinical, magnetic resonance imaging and serum anti-NMO antibodies evaluations.

From MSIF

Latest MS research news | 29 April 2014

Emotional and neutral verbal memory impairment in multiple sclerosis

MS and CIS subjects show a defective emotional enhancement of verbal memory. The inclusion of emotional memory enhancement strategies into the cognitive rehabilitation process should be evaluated to delay memory decline in CIS patients and in early MS.

From MSIF

Latest MS research news | 22 April 2014

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Atacicept treatment in MS is associated with a reduction in serum immunoglobulin concentrations and numbers of circulating mature B cells, but with an increase in relapses.

From MSIF

Latest MS research news | 22 April 2014

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis

This document provides a guide to the most known complementary and alternative medicine therapies used in MS including oral cannabinoids, sativex oromucosal cannabinoid spray, ginkgo biloba, reflexology and magnetic therapy.

From MSIF

Latest MS research news | 15 April 2014

Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and MS lesions

The study provides the first comprehensive overview of the cellular distribution of key nutrient transporters (i.e. glucose and monocarboxylate transporters) in white matter brain samples in the central nervous system tissue of non-neurological and MS patients.

From MSIF

Latest MS research news | 15 April 2014

Oral ponesimod in relapsing–remitting MS: a randomised phase II trial

Once-daily treatment with ponesimod significantly reduces new lesion onset and shows a beneficial clinical effect in patients with RRMS. The treatment is also associated with a lower annualised relapse rate and an increase in the time to first confirmed relapse. Ponesimod is generally well tolerated, but 24-week treatment duration of this study limits the provision of long-term safety and clinical efficacy data.

From MSIF

Latest MS research news | 15 April 2014

Safety and efficacy of fingolimod in patients with relapsing-remitting MS

The study confirms that fingolimod can improve relapse-related outcomes and reduce brain volume loss compared to patients treated with placebo, while it doesn’t shows a statistically significant effect on disability progression.

From MSIF

Latest MS research news | 08 April 2014

Isolated cognitive relapses in MS

This study investigated the relevance of isolated cognitive relapses in patients with relapsing-remitting MS. The researchers defined an isolated cognitive relapse as a transient reduction in cognitive functioning not associated with other subjective or objective neurological symptoms.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial